This week in Drug Discovery (15 – 19 December)
News round-up for 15 – 19 December by Bruno Quinney, Content Team at DDW.
This week in DDW, a research team found that a hidden molecular switch fuels obesity. Elsewhere, AI-generated antibodies have been tolerated by human immune cells.
The top stories:
Scientists discover hidden molecular switch that fuels obesity
A research team from Chonnam National University Medical School, Republic of Korea, discovered a new role of Ret finger protein (RFP) in driving fat cell formation and metabolism.
Read more…
New agreement to reshape EU pharmaceutical legislation
A landmark political agreement has been reached by the European Commission, the European Parliament and the Council of the European Union on a comprehensive reform of the EU pharmaceutical legislation.
FDA approves first gene therapy for Wiskott-Aldrich syndrome
The US Food and Drug Administration (FDA) has approved Waskyra (etuvetidigene autotemcel), the first cell-based gene therapy for the treatment of Wiskott-Aldrich syndrome (WAS).
AI-generated antibodies tolerated by human immune cells
The antibody designs, generated by Latent Labs’ AI platform, reportedly displayed drug-like properties, including low ex vivo immunogenicity.
Charles River to support companies developing therapeutics
Charles River Laboratories has announced drug discovery companies will receive scientific and commercial expertise as part of the second cohort of its Cell and Gene Therapy Incubator Program (CIP).
